MedTrace Logo

Tissue Study of Bv8/PK-2 Inhibition in Human Cancer

NCT01656824 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2013-11-21

No results posted yet for this study

Summary

Study hypothesis is that inhibition of Bv8 production in bone marrow cells of a mice wil reduce the rate of growth of a primary human tumor implanted in the mice. we will take mice and transform their bone marrow cells into non-Bv8 producing cells. than we will implant primary human tumor tissue (taken from surgical specimens after informed consent)in those mice and follow-up on the mice.

Conditions

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Erez Hasnis, MD;PhD · Rambam Health Care Campus

  • Erez Hasnis, MD; PhD. · Rambam Health Care Campus

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656824 on ClinicalTrials.gov